Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) (N-Term) Peptid
VHL
Reaktivität: Human
Wirt: Synthetic
BP, WB
-
- Target Alle VHL Produkte
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Protein Region
- N-Term
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Sequenz
- EDGGEESGAE ESGPEESGPE ELGAEEEMEA GRPRPVLRSV NSREPSQVIF
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-VHL Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Aufreinigung
- Purified
-
Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) peptide
VHL Reaktivität: Human, Ratte, Maus, Hund Wirt: Synthetic BP, Imm
-
- Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Konzentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Synonyme
- HRCA1 Peptide, RCA1 Peptide, VHL1 Peptide, pVHL Peptide, BcDNA:RH61560 Peptide, CG13221 Peptide, DVhl Peptide, Dmel\\CG13221 Peptide, Dvhl Peptide, VHL Peptide, d-VHL Peptide, d-vhl Peptide, dVHL Peptide, dmVHL Peptide, vhl Peptide, rca1 Peptide, vhl1 Peptide, hrca1 Peptide, zgc:158722 Peptide, Vhlh Peptide, von Hippel-Lindau tumor suppressor Peptide, von Hippel-Lindau Peptide, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase Peptide, von Hippel-Lindau disease tumor suppressor Peptide, VHL Peptide, Vhl Peptide, vhl Peptide, CpipJ_CPIJ009992 Peptide
- Hintergrund
-
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Alias Symbols: HRCA1, RCA1, VHL1, pVHL
Protein Interaction Partner: EPAS1,FLNA,FN1,HIF1A,HIF1A,PHF17,USP33,VBP1,CCT3,CUL2,EPAS1,FLNA,FN1,HIF1A,HIF1AN,HIF3A,HNRNPA2B1,PHF17,POLR2G,PSMC3,RBX1,RNF139,SP1,TCEB1,TCEB2,USP33,VBP1,ZNF197,APRT,ATM,ATXN2,CAB39,CCDC59,CCDC82,CCT3,CDK2,CDO1,CHMP2B,CNTF,CSTB,CSTF3,CUL2,CUL5,CYBA,DGKZ
Protein Size: 172 - Molekulargewicht
- 19 kDa
- Gen-ID
- 7428
- NCBI Accession
- NM_198156, NP_937799
-
Sie sind hier:
